产品和服务 / 产品类型 / 细胞系&裂解液 / KO细胞系

Recombinant Rat Leukemia inhibitory factor/LIF Protein (RP01892)

Recombinant Rat Leukemia inhibitory factor/LIF Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.

All(1)|
货号: RP01892
价 格:  620.00
抗体定制
服务咨询
|
扫码下单
享受积分

详细信息

靶点
LIF
细胞系
20.63 kDa
突变描述
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

Mammalian cells such as human, rat and mouse cells are normally diploid with two alleles.
Homozygote: both alleles were knocked out, mRNA has no signal, no expression of proteins.
Heterozygote: only one allele was knocked out, the mRNA transcript levels was decreased compared to wild type, and the protein expression levels was also lower than that of the wild type.
敲除验证
35-45 kDa
产品组成
Ser23-Phe202
物种
HEK293 cells
保存条件
Store at -20℃
运输条件
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

背景信息

Leukemia inhibitory factor (LIF) is a member of Interleukin 6 family. This protein is mainly expressed in the trophectoderm of the developing embryo, with its receptor LIFR expressed throughout the inner cell mass. Mature human LIF shares 78%, 82%, 91%, 88 and 87% aa sequence identity with mouse, rat, canine, bovine, and porcine LIF, respectively. LIF is multifunctional cytokines with many similar activities. LIF is structurally and functionally related to another cytokine, Oncostatin M (OSM), that binds to the high-affinity LIF receptor but not to the low-affinity LIF receptor. While some of the actions of LIF on neurons resemble those of CNTF, LIF also has broad actions outside of the nervous system that in many cases mimic those of interleukin-6 (IL-6).

基因ID
Swiss Prot
别名
CDF; DIA; Differentiation-stimulating Factor; D Factor; Emfilermin; HILDA; Melanoma-derived LPL Inhibitor; MLPLI